In CCA, EphB2 and its ligands (ephrinB1 and ephrinB2) are linked to metastasis, suggesting that targeting EphB2 and its signaling pathway could be a promising strategy for treating CCA. Here, EPHB2 is linked to cholangiocarcinoma.